A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).-MedSci.cn

A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).

Einstein, DJ; Choudhury, AD; Saylor, PJ; Patterson, JC; Croucher, P; Ridinger, M; Erlander, MG; Yaffe, MB; Bubley, G

JOURNAL OF CLINICAL ONCOLOGY, 2021; 39 (6):

科室
- - 订阅+
  - 更多科室
工具
服务